Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

Ussher, John R., Drucker, Daniel J.·2023·Nature Reviews Cardiology

Abstract

Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce body weight, glycaemia, blood pressure, postprandial lipaemia and inflammation - actions that could contribute to the reduction of cardiovascular events. Cardiovascular outcome trials (CVOTs) have demonstrated that GLP1R agonists reduce the rates of major adverse cardiovascular events in patients with T2DM. Separate phase III CVOTs of GLP1R agonists are currently being conducted in people living with heart failure with preserved ejection fraction and in those with obesity. Mechanistically, GLP1R is expressed at low levels in the heart and vasculature, raising the possibility that GLP1 might have both direct and indirect actions on the cardiovascular system. In this Review, we summarize the data from CVOTs of GLP1R agonists in patients with T2DM and describe the actions of GLP1R agonists on the heart and blood vessels. We also assess the potential mechanisms that contribute to the reduction in major adverse cardiovascular events in individuals treated with GLP1R agonists and highlight the emerging cardiovascular biology of novel GLP1-based multi-agonists currently in development. Understanding how GLP1R signalling protects the heart and blood vessels will optimize the therapeutic use and development of next-generation GLP1-based therapies with improved cardiovascular safety.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41569-023-00849-3

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 129 references

Cited by

See all 577

Metadata

Authors
Ussher, J. R., & Drucker, D. J.
Affiliations
  • University of Alberta (CA)
  • Mount Sinai Hospital (CA)
Corresponding author
Drucker, Daniel J.
Venue
Nature Reviews Cardiology
Published
2023-03-28
Volume
20
Issue
7
Pages
463-474
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W4361219083
Cited by
577
References
129
Citations by year
2026: 193 · 2025: 205 · 2024: 156 · 2023: 23
FWCI
20.77
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
GLP-1 receptor agonists, cardiovascular outcomes, type 2 diabetes, obesity, major adverse cardiovascular events, heart failure with preserved ejection fraction, vascular system, cardiovascular safety, blood pressure, postprandial lipemia, inflammation
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. https://app.cochat.ai/papers/10.1038/s41569-023-00849-3
The paper
Ussher, J. R., & Drucker, D. J. (2023). Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-023-00849-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.